AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $245.89. The company's market cap stands at 434.44B, with a P/E ratio of 69.30 and a dividend yield of 2.79%.
During the trading session on 2026-08-08, AbbVie(ABBV) shares reached a daily high of $246.76 and a low of $241.99. At a current price of $245.89, the stock is +1.6% higher than the low and still -0.4% under the high.
Trading volume for AbbVie(ABBV) stock has reached 4.93M, versus its average volume of 6.19M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
...
Key Points AbbVie relies on a high-margin biopharmaceutical portfolio and significant free cash flow to drive shareholder value. Abbott Laboratories leverages...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
Analyst ratings
75%
of 32 ratingsMore ABBV News
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #114 analyst pick,...
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, AbbVie Inc (Symbol: ABBV) has taken over the #60 sp...
Key Points AbbVie posted solid second-quarter financial results, led by its two most important products, Skyrizi and Rinvoq. The company's portfolio and pipel...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
In recent days, AbbVie reported stronger year-on-year second-quarter results, raised its 2026 revenue outlook to about US$67.60 billion, advanced new indication...
Erste Group upgraded AbbVie (ABBV) to Buy from Hold. AbbVie recently raised its 2026 revenue forecast slightly and has made significant progress in its pipeline...
AbbVie (ABBV) lifted its full year 2026 revenue guidance to about US$67.6b, adding US$300m to its outlook, while also issuing third quarter revenue guidance and...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.